Mackay Shields LLC Collegium Pharmaceutical, Inc Transaction History

Mackay Shields LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 04, 2020	SELL	$15.78 - $20.82 $1.9 Million - $2.51 Million	-120,400 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$15.49 - $23.51 $1.26 Million - $1.91 Million	81,400 Added 208.72%	120,400 $2.11 Million
Q1 2020 May 08, 2020	SELL	$13.89 - $25.45 $1.37 Million - $2.51 Million	-98,500 Reduced 71.64%	39,000 $637,000
Q4 2019 Feb 11, 2020	BUY	$10.7 - $22.24 $1.47 Million - $3.06 Million	137,500 New	137,500 $2.83 Million
Q3 2019 Nov 01, 2019	SELL	$10.16 - $13.28 $1.99 Million - $2.6 Million	-195,636 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$10.62 - $16.59 $1.63 Million - $2.54 Million	153,036 Added 359.24%	195,636 $2.57 Million
Q1 2019 May 13, 2019	BUY	$13.58 - $18.72 $433,202 - $597,168	31,900 Added 298.13%	42,600 $645,000
Q4 2018 Feb 14, 2019	SELL	$14.78 - $19.68 $174,404 - $232,224	-11,800 Reduced 52.44%	10,700 $183,000
Q3 2018 Nov 14, 2018	BUY	$14.16 - $24.3 $318,600 - $546,750	22,500 New	22,500 $332,000

256

38.6M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.02B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

Stay updated on Mackay Shields LLC with notifications on news.